Sanofi invested $40 million in Vigil Neuroscience (VIGL.US) as part of its global strategy, leading to a nearly 30% surge in the latter's stock price.

Zhitong Finance · Jun 27 20:16

According to Zhītōng Cáijīng APP, biotechnology company Vigil Neuroscience (VIGL.US) in the clinical stage announced that sanofi (SNY.US) made a strategic investment of 40 million US dollars in the company at a converted price of $7.44 per share. After the announcement, Vigil Neuroscience rose 58.20% in pre-market trading and was up 29.63% as of the time of writing.

It is reported that Sanofi will purchase 537,634 shares of series A non-voting preferred stock of Vigil, which can be converted into 10 shares of common stock per share. Vigil will use the funds to support its R&D activities. The investment return from Sanofi is expected to extend the company's cash flow until 2026.

Sanofi will have exclusive priority negotiation rights for the licensed small molecule TREM2 agonist project at Vigil, including VG-3927, which is currently undergoing phase I clinical research.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

获赛诺菲安万特(SNY.US)战略投资4000万美元，Vigil Neuroscience(VIGL.US)大涨近30%

Sanofi invested $40 million in Vigil Neuroscience (VIGL.US) as part of its global strategy, leading to a nearly 30% surge in the latter's stock price.

Risk Disclaimer

Statement